menu search

ORMP / Oramed: NASH Biotech Play With Added Bonus

Oramed: NASH Biotech Play With Added Bonus
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of concept. Results from the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes are expected in January of 2023. Read More
Posted: Dec 7 2022, 03:49
Author Name: Seeking Alpha
Views: 102544

ORMP News  

Why Oramed Pharmaceuticals Stock Is Crashing Today

By The Motley Fool
January 12, 2023

Why Oramed Pharmaceuticals Stock Is Crashing Today

The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes. more_horizontal

Why Is Oramed (ORMP) Stock Down 75% Today?

By InvestorPlace
January 12, 2023

Why Is Oramed (ORMP) Stock Down 75% Today?

Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing th more_horizontal

Oramed's oral insulin pill fails; stock is down 72%

By Market Watch
January 12, 2023

Oramed's oral insulin pill fails; stock is down 72%

Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral ins more_horizontal

Oramed: NASH Biotech Play With Added Bonus

By Seeking Alpha
December 7, 2022

Oramed: NASH Biotech Play With Added Bonus

Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary expl more_horizontal

Why Oramed Pharmaceuticals Stock Is On Fire Today

By The Motley Fool
July 12, 2022

Why Oramed Pharmaceuticals Stock Is On Fire Today

The biotech's stock has been ripping higher of late. more_horizontal

Oramed And Oral Insulin: Can This Small Company Really Do It?

By Seeking Alpha
April 14, 2022

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. more_horizontal


Search within

Pages Search Results: